Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 2, 2014, Pages 135-145

  Pilotto, Sara ^a   Di Maio, Massimo ^b   Peretti, Umberto ^a   Kinspergher, Stefania ^a   Brunelli, Matteo ^a   Massari, Francesco ^a   Sperduti, Isabella ^c   Giannarelli, Diana ^c   De Marinis, Filippo ^d   Tortora, Giampaolo ^a   Bria, Emilio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b National Cancer Institute   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Afatinib; Erlotinib; Ethnicity; Gefitinib; Lung cancer; Meta analysis; Trial design

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CLINICAL EFFECTIVENESS; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; ETHNIC DIFFERENCE; ETHNICITY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GENE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; GENETICS; LUNG NEOPLASMS; META ANALYSIS; MUTATION; REGRESSION ANALYSIS;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS;

EID: 84897571862     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.11.005     Document Type: Review

References (27)

1. Chou T.Y., Chiu C.H., Li L.H., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005, 11:3750-3757.
2. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
3. Gridelli C., Ciardiello F., Gallo C., et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012, 30:3002-3011.
4. Han J.Y., Park K., Kim S.W., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
5. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
6. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
7. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
8. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
9. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
10. Sequist L.V., Yang J.C., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
11. Wu Y.L., Zhou Z., Hu C.-P., et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013, 31(Suppl). [abstr 8016].
12. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003, 290:2149-2158.
13. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
14. D'Angelo S.P., Pietanza M.C., Johnson M.L., et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011, 29:2066-2070.
15. Bria E., Milella M., Cuppone F., et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol 2011, 22:2277-2285.
16. Di Maio M., Gallo C., De Maio E., et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 2010, 67:127-135.
17. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
18. Pignon J.P., Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2001, 2:475-482.
19. Bria E., Gralla R.J., Raftopoulos H., et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2008, 63:50-57.
20. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of intervention 4.2.6. The Cochrane Library 2006, John Wiley & Sons, Ltd., Chichester, UK, [updated sep 2006].
21. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
22. Tierney J.F., Stewart L.A., Ghersi D., et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
23. Altman D.G., Bland J.M. Interaction revisited: the difference between two estimates. Br Med J 2003, 326:219.
24. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999, 18:2693-2708.
25. Douillard J., Ostoros G., Cobo M., et al. Efficacy, safety and tolerability results froma a phase IV, open-label, single arm study of 1st line gefitinib in caucasian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Lung Cancer 2013, 80:S31.
26. De Luca A., Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010, 11:851-864.
27. Wu J.Y., Yu C.J., Chang Y.C., et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011, 17:3812-3821.